CSI Market
Sign In | Register

Vyne Therapeutics Inc (VYNE) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access VYNE Annual Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Vyne Therapeutics Inc adapts its cash strategy across cycles.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income-13.08
Depreciation & amortization0.01
Amortization of Other Assets-0.02
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Business0.00
Share-based Compensation0.91
Income (Loss) from Equity Method Investments0.00
Adjustment of Warrants Granted for Services0.00
Depreciation Depletion and Amortization Excluding Amortization of Discounts and Premiums-
Increase Decreasein Prepaid Expenses and Other Current Assets-
Depreciation Depletion And Amortization Excluding Amortization Of Discounts And Premiums-
Increase Decrease In Operating Lease Liability-
Goodwill And Intangible Asset Impairment-
Contingent Stock Consideration Remeasurement Gain Loss-
Increase Decrease In Employee Severance Liability Net Of Retirement Fund Profits-
Noncash Or Part Noncash Acquisition Value Of Assets Acquired-
Gain Loss On Sale And Disposition Of Fixed Assets-
Decrease Increase In Prepaid Expenses Other Assets And Operating Lease Right Of Use Asset-
Income taxes0.00
Unrealized Gain (Loss) on Investments0.00
Increase (Decrease) in Receivables0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities-0.84
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.46
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities7.52
Discontinued operations-0.11
Net Cash flow from Operating Activities-6.07
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities5.00
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Proceeds From Business Merger-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-0.01
Discontinued operations0.00
Net Cash Flow from Investing Activities5.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.03
Proceeds From Issuance Of Common Stock Under At The Market Offering-
Proceeds From Debt Financing And Issuance Of Warrants Net Of Issuance Costs-
Other Significant Noncash Transaction Value Of Consideration Received-
Stock Issued-
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-
Capital Lease Obligations Incurred-
Payments Proceeds From Stock Options Exercised Net-0.02
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents24.03
Withholdings From Stock Option Exercises Net-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-0.03
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-6.07
Total Cash Flow-1.10
4 historic quarters locked

Sign in to unlock the full Vyne Therapeutics Inc cash flow history.

Sign In Create Free Account

About Yarrow Bioscience Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001566044-26-000010

Figures are derived from filed reports and may be restated. Historical data is subject to revision.